Practical fundraising intel for founders chasing their first check.
Some checks come with a silent partner. Others come with a second founder who never quit their day job. Here's how to spot the difference, push back without blowing up the relationship, and know when it's time to buy your investor out.
Every 'pass' email from an investor contains more intelligence than most founders realize. Here's how to decode the language, sort the soft no's from the hard no's, and file each rejection where it belongs: in your pipeline, not your trash folder.
Some weeks the inbox just breaks you: three passes, a soft maybe, and a term sheet that quietly lapsed while you were on a plane. Here's how to survive the mid-raise pileup without torching your pipeline or your confidence.
The most hands-on investor in your round might also be the most dangerous one. Here's how over-involved angels quietly capture early-stage companies — and the boundary-setting scripts to use before the money hits your account.
A tiny angel check feels like validation until you realize it came with a board seat or observer rights that outlive the relationship. Here's how a minor early investor can hijack your Series A — and what to offer instead.
Every inactive angel on your cap table is a small liability that compounds at Series A. Here's how lead investors actually price dead equity, when buybacks happen, and the diligence to run before you cash a single angel check.
Landing your first term sheet feels like winning the lottery — until a second one shows up and you realize you have no idea how to juggle both. Here's the honest timeline, the scripts, and the unforced errors that turn two eager investors into zero.
Founders raising $150K-$300K keep swiping templates built for $3M seed rounds — and it shows. Here's how the deck itself should shrink, shift, and get honest when you're asking for less.
Demo days promise a concentrated room full of capital, but the reality is 50 companies competing for the same 30 check-writers who see every pitch back-to-back. Here's why batch-based raising produces terrible conversion — and the 90-day recovery plan that actually closes rounds.
Most first-time founders skim a term sheet, celebrate the valuation, and sign whatever their lawyer waves through. But the clauses that actually hurt you — drag-along, pay-to-play, redemption rights — rarely announce themselves. Here's the risk ranking your attorney should be giving you, plus the five questions you're not asking.
Most founders go dark when things get ugly, and that's exactly when silence costs them their next round. Here's how to write the update nobody wants to send — what to disclose, what to frame, and which number to lead with.
Most founders treat investor updates as homework. Done right, that monthly email is the cheapest, most effective pre-marketing your next round will ever get. Here's what to send, what to cut, and why the investors who passed are your best subscribers.
Raising 'two years of runway' sounds like a cushion, but the math behind it usually buys you far less breathing room than founders think. Here's how to stress-test your runway against real hiring plans, slow revenue, and the Series A clock.
Most founders treat the SAFE cap as a throwaway number — something to negotiate in five minutes so they can get back to building. But that figure becomes the reference point your Series A investors will use to price your company, and picking the wrong one can trap you in down-round territory before you've even raised a priced round.
Investors can smell a raise that started out of panic. Here's the 90-day audit that turns your finances, metrics, and pitch into something fundable before the first intro goes out.
The 'team risk' objection often lands before you've pitched anything at all. A look at when the solo-founder bias is legitimate, when it's a lazy excuse, and how successful solo founders fight back.
Investors almost never say no outright — they say things that sound like maybes. Here's a working translation of the most common soft passes, plus a triage system for deciding which conversations to revive and which to bury.
Spray-and-pray fundraising feels productive, but it's quietly torching your round. A look at why volume kills momentum — and how a tight, sequenced list of 20 real targets outperforms a thousand cold emails every time.
Most founders treat cold outreach like a lottery ticket when they should treat it like a sales pipeline. We crunched the numbers on where leads actually die — and it's rarely the first email.
Most bridge rounds are built for the investors writing them, not the founders signing them. Here's how bridges go wrong — PETS, ratchets, crowding out — and how to decide whether you should bridge at all.